Department of Obstetrics and Gynecology, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510700, China.
Department of Pathology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China.
BMC Cancer. 2017 Oct 4;17(1):673. doi: 10.1186/s12885-017-3650-5.
Our previous study showed FOXM1 expression was significantly up-regulated in cervical cancer, and was associated with poor prognosis. To clarify miRNAs-FOXM1 modulation pathways, in this study, we investigated the relationships between miR-216b and FOXM1 and the role of miR-216b in cell proliferation and prognosis of cervical cancer patients.
Western blotting and qPCR were used to determine expression of FOXM1, cell cycle related factors and miR-216b level. MiR-216b overexpression and inhibited cell models were constructed, and siRNA was used for FOXM1 silencing. Cell proliferation was analyzed by MTT and colony formation assay. Dual luciferase reporter assay system was used to clarify the relationships between miR-216b and FOXM1. Kaplan-Meier survival analysis was used to evaluate prognosis.
MiR-216b was down-regulated in cervical cancer cells and tissues, and its ectopic expression could decrease cell proliferation. Western blotting analysis showed miR-216b can inhibit cell proliferation by regulating FOXM1-related cell cycle factors, suppressing cyclinD1, c-myc, LEF1 and p-Rb and enhancing p21 expression. Repressing of miR-216b stimulated cervical cancer cell proliferation, whereas silencing FOXM1 expression could reverse this effect. Western blotting and luciferase assay results proved FOXM1 is a direct target of miR-216b. Survival analysis showed higher level of miR-216b was associated with better prognosis in cervical cancer patients.
FOXM1 expression could be suppressed by miR-216b via direct binding to FOXM1 3'-UTR and miR-216b could inhibit cell proliferation by regulating FOXM1 related Wnt/β-catenin signal pathway. MiR-216b level is related to prognosis in cervical cancer patients and may serve as a potential prognostic marker.
我们之前的研究表明,FOXM1 在宫颈癌中表达显著上调,并与不良预后相关。为了阐明 miRNAs-FOXM1 调控途径,本研究探讨了 miR-216b 与 FOXM1 的关系以及 miR-216b 在宫颈癌患者细胞增殖和预后中的作用。
采用 Western blot 和 qPCR 检测 FOXM1、细胞周期相关因子和 miR-216b 水平。构建 miR-216b 过表达和抑制细胞模型,并采用 siRNA 沉默 FOXM1。采用 MTT 和集落形成实验分析细胞增殖。双荧光素酶报告基因检测系统阐明 miR-216b 与 FOXM1 的关系。Kaplan-Meier 生存分析评估预后。
miR-216b 在宫颈癌细胞和组织中下调,其过表达可降低细胞增殖。Western blot 分析表明,miR-216b 通过调节 FOXM1 相关细胞周期因子抑制细胞增殖,下调 cyclinD1、c-myc、LEF1 和 p-Rb,上调 p21 表达。抑制 miR-216b 可刺激宫颈癌细胞增殖,而沉默 FOXM1 表达可逆转此效应。Western blot 和荧光素酶检测结果证实 FOXM1 是 miR-216b 的直接靶标。生存分析显示,宫颈癌患者 miR-216b 水平较高与预后较好相关。
miR-216b 可通过直接结合 FOXM1 3'-UTR 抑制 FOXM1 表达,通过调节 FOXM1 相关 Wnt/β-catenin 信号通路抑制细胞增殖。miR-216b 水平与宫颈癌患者的预后相关,可能作为潜在的预后标志物。